Journal List > World J Mens Health > v.36(1) > 1088862

Kim, Kim, Oh, Chung, Yoon, Jung, and Kim: Enucleated Weight/Enucleation Time, Is It Appropriate for Estimating Enucleation Skills for Holmium Laser Enucleation of the Prostate? A Consideration of Energy Consumption

Abstract

Purpose

To date, the parameters for evaluating enucleation efficiency have only considered enucleation time, although operators simultaneously consume both time and energy during holmium laser enucleation of the prostate. This study was undertaken to find a better way of assessing enucleation skills, considering both enucleation time and consumed energy.

Materials and Methods

One hundred (n=100) consecutive patients who underwent holmium laser enucleation of the prostate from April 2012 to April 2014 by a single surgeon were enrolled. Ten groups of 10 consecutive cases were used to analyze the parameters of enucleation efficiency.

Results

The mean enucleation time, consumed energy, and enucleated weight were 41.3±19.2 minutes, 66.2±36.0 kJ, and 26.6±21.8 g, respectively. Concerning learning curves, like enucleation time-efficacy (=enucleated weight/enucleation time), enucleation energy-efficacy (=enucleated weight/consumed energy) also had an increasing tendency. Enucleation ratio efficacy (=enucleated weight/transitional zone volume/enucleation time) plateaued after 30 cases. However, enucleation time-energy-efficacy (=enucleated weight/enucleation time/consumed energy) continued to increase after 30 cases and plateaued at 61 to 70 cases. Furthermore, one-way analysis of variance showed that group means for enucleation time-energy-efficacy (F=3.560, p=0.001) were significantly different, but that those of enucleation ratio efficacy (F=1.931, p=0.057) were not.

Conclusions

When both time and energy were considered, enucleation skills continued to improve even after 30 cases and plateaued at 61 to 70 cases. Therefore, we propose that enucleation time-energy-efficacy should be used as a more appropriate parameter than enucleation ratio efficacy for evaluating enucleation skills.

INTRODUCTION

Holmium laser enucleation of the prostate (HoLEP) makes it possible to remove an entire enlarged adenoma confidently in the natural-tissue plane of the surgical capsule. A recent study reported that HoLEP is a safe and effective treatment for benign prostatic hyperplasia (BPH) among the elderly [1]. Compared with younger patients, patients aged ≥80 years had similar overall morbidity and 6-month functional outcomes after HoLEP [1]. Thus, HoLEP is considered a safe and effective treatment modality for bladder outlet obstruction (BOO) related to BPH, and has been reported to have lower morbidity rates than other modalities [2]. Comparisons with conventional treatment modalities have shown that HoLEP has excellent hemostatic properties and causes less electrolyte deterioration [345]. Furthermore, in view of its effectiveness, it has been suggested that HoLEP offers a possible alternative to open prostatectomy [67].
Since the first clinical report on HoLEP was published by Gilling et al [8] in 1996, several randomized controlled trials have been conducted. HoLEP produces clinical outcomes that are similar to those of transurethral resection of the prostate (TURP) and open prostatectomy, but has lower postoperative complication rates and shorter hospital stays [5691011]. In addition, HoLEP appears to be a true endourological alternative to open prostatectomy, because it can treat very large prostates more effectively [1213].
Although the technique has been refined and its popularity has increased, HoLEP faces major impediments to its widespread application. In particular, the endoscopic technique is challenging and appears to be difficult to learn, meaning that HoLEP has a steep learning curve. Furthermore, these difficulties have delayed its adoption by the urological community [14].
Several reports have investigated the learning curve of HoLEP [361415]. Some authors have argued that a surgeon needs experience with between 20 and 30 cases to attain competency [36], while others have argued that up to 50 cases are needed [1415]. These discrepancies are mainly caused by the absence of an accurate means of evaluating the operative learning curve, that is, the lack of a proper parameter for estimating the operator's enucleation skills.
To date, researchers have attempted to identify parameters that can be used to determine how many cases are needed to attain competency. However, the most important consideration is which parameter is more sensitive for the evaluation of enucleation skills. Enucleation efficacy [141516] and enucleation ratio (ER) efficacy (ERE) [17] have been used to plot the learning curve, but both focus on time and do not consider energy, although operators simultaneously consume both time and energy during HoLEP.
Therefore, the present study was undertaken to develop a new parameter suitable for estimating the operator's enucleation skills that includes a consideration of energy consumption.

MATERIALS AND METHODS

1. Ethics statement

The present study protocol was reviewed and approved by the Institutional Review Board of Gachon University Gil Medical Center, Incheon, Republic of Korea (approval number: GAIRB2015-85). Informed consent was submitted by all subjects when they were enrolled.

2. Subject

One hundred consecutive patients who underwent HoLEP for BPH from April 2012 to April 2014 were enrolled. All patients were treated by a single surgeon. Perioperatively, the enucleation time and consumed energy were recorded and the enucleated weight was measured. The perioperative clinical variables, including ER (=enucleated weight/transitional zone volume [TZV]), ERE (=ER/enucleation time), enucleation time-efficacy (ETE=enucleated weight/enucleation time), enucleation energy-efficacy (EEE=enucleated weight/consumed energy), and enucleation time-energy-efficacy (ETEE=enucleated weight/enucleation time/consumed energy) were analyzed.
An 80-W OmniPulse MAX® (Trimedyne Inc., Irvine, CA, USA) was used for HoLEP, which was performed as described by Gilling et al [18]. With the patient placed in the lithotomy position under spinal anesthesia (spinal anesthesia was usually preferred), the urethra was dilated with a 30-Fr metal catheter, and a working sheath was introduced. The energy source consisted of an 80-W holmium: yttrium aluminium garnet laser with a 550-µm end-firing laser fiber (FlexMAX®; Trimedyne Inc.). A 26-Fr resectoscope (Karl Storz™) with a laser bridge was used, and normal saline irrigation was performed continuously. The enucleated prostatic tissue was removed by transurethral morcellation using a mechanical morcellator (Richard Wolf, Knittlingen, Germany) that was introduced through an offset rigid nephroscope. The bladder was maintained in a distended condition during morcellation. Lubricants were applied to the scope intermittently throughout the procedure. At the end of surgery, a 22-Fr 3-way urethral Foley catheter was placed in situ for continuous postoperative irrigation. In general, the flow of irrigation fluid was reduced gradually and cut off the morning after surgery. The urethral catheter was removed after confirming the cessation of hematuria.

3. Statistical analysis

Basic data were expressed using descriptive statistics. Groups of 10 consecutive cases were used to analyze enucleation efficiency. Statistical analyses were performed by one-way analysis of variance (ANOVA) with the post hoc Tukey test. To estimate the sensitiveness of the different parameters for assessing enucleation efficiency, we calculated the coefficient of variation (CV=standard deviation [SD]/mean×100 [%]), which provides a standardized measure of a probability or frequency distribution. Analyses were performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA), and differences were considered statistically significant when p-values were less than 0.05.

RESULTS

The mean patient age and preoperative prostate specific antigen level were 68.8±6.2 years and 4.44±6.22 ng/mL, respectively (Table 1). The mean total prostate volume and TZV were 61.3±28.9 mL and 33.1±22.8 mL, respectively (Table 1).
The mean enucleation time and consumed energy were 41.3±19.2 minutes and 66.2±36.0 kJ, respectively (Table 2). The mean enucleated weight and ER were 26.6±21.8 g and 0.753±0.238 g/mL, respectively (Table 2). The mean ETE and EEE were 0.616±0.366 g/min and 0.397±0.217 g/kJ, respectively (Table 2). The mean ERE and ETEE were 0.021±0.009 g/mL/min and 0.011±0.007 g/min/kJ, respectively (Table 2).
The CVs of enucleated weight and ER were 82.0% and 31.6%, respectively (Table 2), and the CVs of ETE and EEE were 59.4% and 54.7%, respectively (Table 2). The CVs of ERE and ETEE were 42.9% and 63.6%, respectively (Table 2).
In the present study, the 100 patients were divided into 10 groups of 10 consecutive cases. The groups were named as follows: cases 1~10 as groups 1, cases 11~20 as group 2, cases 21~30 as group 3, cases 31~40 as group 4, cases 41~50 as group 5, cases 51~60 as group 6, cases 61~70 as group 7, cases 71~80 as group 8, cases 81~90 as group 9, and cases 91~100 as group 10. Table 3 summarizes the changes in operative parameters for these 10 groups of 10 consecutive cases. ANOVA showed that the group mean values of ETE (F=2.350, p=0.020), EEE (F=2.060, p=0.042), and ETEE (F=3.560, p=0.001) were significantly different, but that those of ER (F=0.999, p=0.447) and ERE (F=1.931, p=0.057) were not (Table 3).
ER had a smaller SD than enucleated weight because ER was designed to reduce the distribution spread caused by different enucleated weights. In particular, in cases 41~50 (group 5), the SD of ER was much smaller than that of enucleated weight (Fig. 1). Gradual decreases in both enucleation time and consumed energy were observed with increasing case numbers. Like enucleation time, consumed energy also tended to decrease after 20 cases (group 2) and plateaued at 61~70 cases (group 7) (Fig. 2). Gradual improvements were observed in both ETE and EEE. Like ETE, EEE also tended to increase (Fig. 3). The curve of ERE plateaued after 30 cases (group 3), but that of ETEE increased after 30 cases (group 3) and plateaued at 61~70 cases (group 7), which indicates that the operator's enucleation skills continued to increase even after 30 cases (group 3) (Fig. 4).

DISCUSSION

BPH is very common in elderly men. In the Baltimore Longitudinal Study of Aging, almost 60% of 60-year-olds had some degree of clinical BPH [19]. TURP has been considered the gold standard surgical treatment for BPH [20]. Recently, surgical techniques using lasers, such as photoselective vaporization of the prostate, HoLEP and thulium laser enucleation of the prostate have been increasingly adopted, with a number of reports documenting their merits.
Laser prostatectomy has continuously evolved since Gilling et al [21] first described HoLEP in 1995. In 1998, the concept of morcellation was adopted and the technique was applied to patients with BOO [18]. However, the steep operative learning curve of HoLEP has hindered its widespread use, despite its advantages.
Researchers have tried to identify parameters that show how many cases of experience are needed to attain competency. However, the sensitivity of a parameter with respect to the evaluation of enucleation skills is probably more important. To date, enucleation efficacy [141516] and ERE [17] have been used as parameters for the HoLEP learning curve, but they focus on time alone, although operators simultaneously consume time and energy during HoLEP.
The present study is the first to confirm that like enucleation time, energy consumption also decreases as the enucleation technique of a single surgeon develops (Fig. 2). In the present study, we sought to identify a parameter that considers both time and energy. Our results demonstrate that even after 30 cases (group 3), enucleation skills continued to improve (Fig. 4). In addition, we found that ETEE provided a more sensitive means of evaluating enucleation skills than ERE. In other words, rather than simply assessing the efficiency of the enucleation technique in terms of enucleation time, as in previous studies about the HoLEP learning curve, it is better to assess the efficiency of the enucleation technique with ETEE, which is a parameter that combines time and energy usage (Fig. 4).
The CV provides a standardized measure of the dispersion of a probability distribution or frequency distribution, and is calculated by dividing the SD by the mean. The CV is useful because the SD of data must be understood in the context of the mean value. For comparisons between data sets with different units or widely different means, one should use the CV instead of the SD.
In the present study, we used the CV as the scale to assess the sensitivity of each parameter for enucleation efficiency. In fact, ER was designed to reduce the variance caused by enucleated weight [17], and thus, ER had a lower CV than enucleated weight (31.6% vs. 82.0%) (Table 2, Fig. 1). Similarly, ERE (42.9%), which is derived from ER, had a lower CV than ETE (59.4%), EEE (54.7%), and ETEE (63.6%) (Table 2), which means that ETEE had a much wider distribution than ERE, and thus, ETEE was more sensitive than ERE for evaluating enucleation skills.
In the present study, ANOVA showed that mean ETEE values changed significantly with time; that is, they were significantly different across the 10 groups of 10 consecutive cases (p=0.001), whereas no significant changes were found for ERE (p=0.057) (Table 3). This means that ETEE is more suitable than ERE for showing improvements in enucleation skills.
ER is defined as the ratio of the enucleated weight to the TZV. Thus, ER seems to be a fixed constant value, and it did not increase as enucleation skills improved. ER could increase depending on the improvement of device (morcellator) performance, allowing it to retrieve the enucleated prostate tissue without loss. Therefore, we think that ERE, which is derived from ER, does not provide a sensitive evaluation of the surgeon's enucleation skills, as ER is designed to reduce the variance of enucleated weight [17].
In the present study, ERE plateaued after 30 cases (group 3), which is similar to the study by Jeong et al [17]. However, ETEE continued to increase even after 30 cases (group 3) and plateaued at 61~70 cases (group 7) (Fig. 4). This indicates that for cases 31~40 (group 4), the plateau of ERE did not indicate a real attainment of competency in enucleation skills. Therefore, we think that ETEE, which considers enucleation time and consumed energy simultaneously, is more sensitive for evaluating enucleation skills than previous parameters (including ETE and ERE) that only consider enucleation time.
The present study has several limitations. First, it is intrinsically limited by its retrospective design, despite the enrollment of consecutive patients to avoid potential selection bias. Second, the study was conducted on patients operated on by a single surgeon. Accordingly, we suggest that ETEE should be evaluated in group of several surgeons in the future, to determine if it is generally acceptable. Third, we did not investigate whether energy usage varied according to patients' bleeding tendency and vascular distribution except for prostate size, although the amount of laser energy used may vary depending on those factors, as well as prostate volume and TZV. Although no accurate information was available regarding patients' bleeding tendency, in the early stages of HoLEP surgery, surgeons generally perform surgery on patients who are not likely to bleed because of their deficient surgical technique. As the surgeon's technique gradually develops, patients with bleeding tendencies can be operated on. However, as shown in Fig. 2 of this study, energy consumption decreased as the technique developed. This means that less energy is used as the surgeon's enucleation skill develops. Therefore, we think that this clearly shows that in the HoLEP learning curve, the development of the enucleation technique can be evaluated not only by time, but also by energy usage (Fig. 3) and that ETEE is more sensitive for evaluating the enucleation skills than previous parameters (including ETE and ERE) (Fig. 4). Furthermore, in clinical settings after the surgeon's enucleation skill has fully developed, we believe that ETEE can quantitatively measure the difficulty of enucleation due to the patient's bleeding tendency and vascular distribution.

CONCLUSIONS

Several previous parameters (including ETE and ERE) for evaluating enucleation skills only consider enucleation time. However, ETEE simultaneously considers enucleation time and consumed energy. The curve of ERE plateaued after 30 cases, but that of ETEE showed that even after 30 HoLEP cases, enucleation skills continued to improve. Therefore, we propose that ETEE should be used as a more appropriate parameter than ERE for evaluating enucleation skills.

ACKNOWLEDGEMENTS

This study was supported by a grant from the National Research Foundation of Korea (NRF-2017R1A2B2005412).

Notes

Disclosure: The authors have no potential conflicts of interest to disclose.

Author Contribution: Research conception & design: Kim TB. Performing the experiments: Kim TB. Data acquisition: Kim KT, Chung KJ. Data analysis and interpretation: Jung H, Yoon SJ. Statistical analysis: Oh JK, Kim TB. Drafting of the manuscript: Kim KH. Critical revision of the manuscript: Kim KH, Kim TB. Receiving grant: Kim KH. Approval of final manuscript: all authors.

References

1. Piao S, Choo MS, Kim M, Jeon HJ, Oh SJ. Holmium laser enucleation of the prostate is safe for patients above 80 years: a prospective study. Int Neurourol J. 2016; 20:143–150. PMID: 27377947.
crossref
2. Chilton CP, Mundy IP, Wiseman O. Results of holmium laser resection of the prostate for benign prostatic hyperplasia. J Endourol. 2000; 14:533–534. PMID: 10954312.
crossref
3. Moody JA, Lingeman JE. Holmium laser enucleation for prostate adenoma greater than 100 gm.: comparison to open prostatectomy. J Urol. 2001; 165:459–462. PMID: 11176396.
4. Westenberg A, Gilling P, Kennett K, Frampton C, Fraundorfer M. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup. J Urol. 2004; 172:616–619. PMID: 15247745.
crossref
5. Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004; 172:1926–1929. PMID: 15540757.
crossref
6. Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.: a randomized prospective trial of 120 patients. J Urol. 2002; 168:1465–1469. PMID: 12352419.
crossref
7. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol. 2006; 49:87–91. PMID: 16314033.
crossref
8. Gilling PJ, Cass CB, Cresswell MD, Fraundorfer MR. Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Urology. 1996; 47:48–51. PMID: 8560662.
crossref
9. Gupta N, Sivaramakrishna , Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int. 2006; 97:85–89. PMID: 16336334.
10. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curve. Eur Urol. 2007; 52:1465–1471. PMID: 17498867.
crossref
11. Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup. J Urol. 1999; 162:1640–1644. PMID: 10524887.
crossref
12. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008; 53:160–166. PMID: 17869409.
crossref
13. Humphreys MR, Miller NL, Handa SE, Terry C, Munch LC, Lingeman JE. Holmium laser enucleation of the prostate--outcomes independent of prostate size? J Urol. 2008; 180:2431–2435. PMID: 18930490.
crossref
14. Shah HN, Mahajan AP, Sodha HS, Hegde S, Mohile PD, Bansal MB. Prospective evaluation of the learning curve for holmium laser enucleation of the prostate. J Urol. 2007; 177:1468–1474. PMID: 17382757.
crossref
15. Seki N, Mochida O, Kinukawa N, Sagiyama K, Naito S. Holmium laser enucleation for prostatic adenoma: analysis of learning curve over the course of 70 consecutive cases. J Urol. 2003; 170:1847–1850. PMID: 14532790.
crossref
16. Bae J, Oh SJ, Paick JS. The learning curve for holmium laser enucleation of the prostate: a single-center experience. Korean J Urol. 2010; 51:688–693. PMID: 21031088.
crossref
17. Jeong CW, Oh JK, Cho MC, Bae JB, Oh SJ. Enucleation ratio efficacy might be a better predictor to assess learning curve of holmium laser enucleation of the prostate. Int Braz J Urol. 2012; 38:362–371. PMID: 22765867.
crossref
18. Gilling PJ, Kennett K, Das AK, Thompson D, Fraundorfer MR. Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol. 1998; 12:457–459. PMID: 9847070.
crossref
19. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The baltimore longitudinal study of aging. Urology. 1991; 38:S4–S8.
20. AUA Practice. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170:530–547. PMID: 12853821.
21. Gilling PJ, Cass CB, Malcolm AR, Fraundorfer MR. Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience. J Endourol. 1995; 9:151–153. PMID: 7633476.
crossref
Fig. 1

Enucleated weight and enucleation ratio (ER). ER had a lower standard deviation (SD) than enucleated weight, because ER was designed to reduce the variance shown by enucleated weight. In particular, in cases 41~50 (group 5), the SD of ER was much smaller than that of enucleated weight. The 100 patients were divided into 10 groups of 10 consecutive cases, as follows: cases 1~10 as groups 1, cases 11~20 as group 2, cases 21~30 as group 3, cases 31~40 as group 4, cases 41~50 as group 5, cases 51~60 as group 6, cases 61~70 as group 7, cases 71~80 as group 8, cases 81~90 as group 9, and cases 91~100 as group 10.

wjmh-36-79-g001
Fig. 2

Enucleation time and consumed energy. Gradual decreases in both enucleation time and consumed energy were observed. Like enucleation time, consumed energy also showed a decreasing trend even after 20 cases (group 2) and plateaued at 61~70 cases (group 7).

wjmh-36-79-g002
Fig. 3

Enucleation time-efficacy (ETE) and enucleation energy-efficacy (EEE). Gradual improvements in ETE and EEE were observed. Like ETE, EEE also tended to increase.

wjmh-36-79-g003
Fig. 4

Enucleation ratio efficacy (ERE) and enucleation time-energy-efficacy (ETEE). ERE plateaued after 30 cases (group 3). However, ETEE continued to increase even after 30 cases (group 3) and plateaued at 61~70 cases (group 7). This means that even after 30 cases (group 3), the operator's enucleation skills continued to increase.

wjmh-36-79-g004
Table 1

Characteristics of the study population (n=100)

wjmh-36-79-i001
Variable Mean±standard deviation Median (minimum~maximum)
Age (y) 68.8±6.2 69.0 (56~80)
Height (cm) 166.9±5.5 167.0 (155.0~177.0)
Weight (kg) 67.1±9.3 67.0 (47.0~97.0)
BMI (kg/m2) 24.1±3.0 23.9 (16.7~31.7)
PSA (ng/mL) 4.44±6.22 2.58 (0.19~43.66)
TPV (mL) 61.3±28.9 53.5 (25.1~184.4)
TZV (mL) 33.1±22.8 27.2 (9.4~120.0)
TZV/TPV 0.510±0.141 0.485 (0.298~0.876)

BMI: body mass index, PSA: prostate specific antigen, TPV: total prostate volume, TZV: transitional zone volume.

Table 2

Enucleation-associated variables

wjmh-36-79-i002
Variable Mean±standard deviation Median (minimum~maximum) CV (%)
Enucleation time (min) 41.3±19.2 37.0 (14.0~92.0) 46.5
Consumed energy (kJ) 66.2±36.0 54.158 (23.612~188.309) 54.4
Enucleated weight (g) 26.6±21.8 20.9 (1.5~116.0) 82.0
ER (g/mL) 0.753±0.238 0.800 (0.126~1.200) 31.6
ETE (g/min) 0.616±0.366 0.540 (0.083~1.915) 59.4
EEE (g/kJ) 0.397±0.217 0.374 (0.017~1.044) 54.7
ERE (g/mL/min) 0.021±0.009 0.019 (0.007~0.050) 42.9
ETEE (g/min/kJ) 0.011±0.007 0.010 (0.001~0.045) 63.6

CV: coefficient of variation (=standard deviation/mean×100 [%]), ER: enucleation ratio (=enucleated weight/transitional zone volume), ETE: enucleation time-efficacy (=enucleated weight/enucleation time), EEE: enucleation energy-efficacy (=enucleated weight/consumed energy), ERE: enucleation ratio efficacy (=enucleated weight/transitional zone volume/enucleation time), ETEE: enucleation time-energy-efficacy (=enucleated weight/enucleation time/consumed energy).

Table 3

Learning curve-related operative parameters according to the number of consecutive cases treated (analysis of variance)

wjmh-36-79-i003
Variable TPV TZV EW ET CE ER ETE EEE ERE ETEE
F-value 1.295 1.069 1.305 3.559 4.339 0.999 2.350 2.060 1.931 3.560
p-value 0.251 0.394 0.246 0.001 0.000 0.447 0.020 0.042 0.057 0.001
No. of consecutive cases treated
1~10 62.7±29.9 34.0±24.3 28.7±27.0 52.4±28.9 96.534±33.710 0.725±0.305 0.501±0.385 0.268±0.204 0.016±0.010 0.005±0.004
11~20 67.4±24.5 40.0±20.2 31.0±14.6 59.6±18.7 107.966±45.276 0.784±0.142 0.528±0.186 0.309±0.128 0.015±0.006 0.006±0.004
21~30 56.1±24.0 27.6±22.1 21.4±17.8 52.5±19.9 74.454±48.158 0.744±0.236 0.372±0.189 0.309±0.172 0.015±0.004 0.006±0.004
31~40 50.2±24.0 25.3±17.8 20.6±18.1 38.8±18.8 51.077±29.045 0.759±0.272 0.458±0.221 0.362±0.190 0.021±0.009 0.010±0.004
41~50 66.9±36.0 45.0±32.9 42.0±34.8 44.6±21.2 68.228±39.619 0.899±0.116 0.858±0.286 0.573±0.147 0.024±0.009 0.015±0.007
50~60 51.6±13.8 30.3±13.0 24.3±14.5 36.8±11.2 57.146±18.947 0.754±0.233 0.642±0.324 0.411±0.199 0.021±0.006 0.012±0.006
61~70 54.6±21.8 28.5±18.4 21.7±20.0 30.5±9.4 45.747±22.331 0.665±0.253 0.663±0.468 0.447±0.297 0.023±0.011 0.015±0.012
71~80 55.9±6.5 26.3±6.1 17.7±8.3 30.3±9.0 45.204±13.159 0.650±0.200 0.583±0.250 0.390±0.160 0.022±0.007 0.014±0.007
81~90 62.2±34.1 28.9±19.1 21.8±17.8 30.2±10.6 52.378±20.409 0.697±0.285 0.660±0.425 0.385±0.237 0.024±0.011 0.013±0.008
91~100 83.9±45.7 44.0±35.4 36.1±27.6 37.6±13.6 64.683±22.870 0.836±0.253 0.881±0.505 0.502±0.261 0.024±0.009 0.013±0.005

Values are presented as mean±standard deviation.

TPV: total prostate volume, TZV: transitional zone volume, EW: enucleated weight, ET: enucleation time, CE: consumed energy, ER: enucleation ratio, ETE: enucleation time-efficacy, EEE: enucleation energy-efficacy, ERE: enucleation ratio efficacy, ETEE: enucleation time-energy-efficacy.

TOOLS
Similar articles